What smart money is saying about Enovis Corporation
1 fund in our archive has pitched Enovis Corporation, most recently Royce in March 2025.
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
Get an email when a fund buys, sells or pitches it
Fund signal · last 12 months
3 lettersToo few moves on Enovis Corporation yet for a clear signal
Moves described in fund letters in our archive. A sentence published word for word by several funds of one house in the same quarter counts once.
Position history
Between Q1 2025 and Q3 2026, 3 fund letters reported a position in Enovis Corporation, with 3 sells (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 3 | 0 |
| Q1 2025 | 0 | 0 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 3 positions · 3 moves
- September 2026
“Not every decision works. Enovis was a mistake, and we sold at a loss of around 22%.”
Enovis Corporation - September 2026
“During the quarter three new positions were added to the portfolio and one was eliminated. Quarter Year to Date 1 Year 3 Years 5 Years 10 Years Tributary Capital Management (Gross of Fees) -5.2% 22.4% 21.4% 14.1% 9.0% 9.9% Tributary Capital Management (Net of Fees) -5.4% 21.7% 20.4% 13.2% 8.1% 9.0% Russell 2000 Index -7.2% 13.7% 16.2% 17.7% 6.3% 9.8% Russell 2000 Value Index -4.9% 17.0% 20.8% 17.9% 7.8% 9.4% PORTFOLIO MANAGERS: MARK WYNEGAR & MICHAEL JOHNSON THIRD QUARTER 2026 First Business Financial Services is a business-only bank with no retail branches, $4.3 billion in assets and operates primarily across Wisconsin and Kansas City. Its exclusive commercial focus has driven consistent core deposit growth through competitive pricing and strong treasury management, while attracting private wealth relationships from its commercial client base. An interest rate-neutral balance sheet limits interest rate risk, and a focus on top- quartile borrowers has delivered better-than-peer credit performance. MYR Group is a specialty electrical contractor operating across the U.S. and Canada, serving utilities, data centers, renewable energy and transportation projects. The company owns one of the largest specialized electrical equipment fleets in the industry. A healthy balance sheet provides flexibility for investment, acquisitions and buybacks, while surging electricity demand from AI, data center buildout and an aging grid supports a compelling multi-year growth outlook. UFP Technologies is a contract design and manufacturing partner to the world’s leading medical device companies, producing single-use components and sterile packaging for minimally invasive surgery, wound care, infection prevention and orthopedic applications. The company has been growing much faster than the global outsourcing market and prudent capital allocation has helped produce healthy cash flow margins and returns on invested capital. A senior leadership team averaging over 30 years of combined tenure provides rare continuity and deep industry expertise. During the quarter, we exited our position in Enovis, a manufacturer of artificial joints, surgical implant tools and orthopedic braces.”
Enovis Corporation - September 2026
“Exited: Enovis Corporation (ENOV) – Exited our position reflecting a loss of confidence in management following a recently announced acquisition.”
Enovis Corporation
Fund coverage · 1 thesis
- RoyceMarch 2025
Enovis Corporation is an orthopedic-focused medical technology company poised for high-single-digit organic growth and EBITDA margin expansion after overcoming integration challenges from its 2024 acquisition of Lima.
Read the full thesis
Read every full thesis on Enovis Corporation
Read all 1 thesis in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→